Apr 11, 2022 10:00 am EDT NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022
Apr 11, 2022 7:00 am EDT NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D
Apr 8, 2022 4:05 pm EDT NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022
Mar 17, 2022 3:00 am EDT NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung Cancer
Mar 2, 2022 4:05 pm EST NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
Feb 23, 2022 7:00 am EST NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021
Feb 14, 2022 7:00 am EST NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer
Feb 11, 2022 2:00 am EST NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma
Feb 8, 2022 7:00 am EST NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences
